Status:
COMPLETED
A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum
Lead Sponsor:
Revision Skincare
Collaborating Sponsors:
Stephens & Associates, Inc.
Conditions:
Fine Lines
Wrinkle
Eligibility:
FEMALE
30-60 years
Phase:
NA
Brief Summary
This double-blind, randomized, controlled, single-center clinical trial was conducted to assess the efficacy and tolerance of an anti-aging serum to improve moderate overall photodamage and skin fatig...
Detailed Description
This double-blind, randomized, controlled, single-center clinical trial was conducted to assess the efficacy and tolerance of an anti-aging serum (Cell 1) to improve moderate overall photodamage and s...
Eligibility Criteria
Inclusion
- Female, 30 to 60 years of age
- Fitzpatrick skin type I -IV
- Moderate overall photodamage of the skin
- Moderate lack of firmness (visual) of the skin
- Moderate dull appearance of the skin
- Subjects must be willing to withhold all facial treatments during the course of the study and have not undergone a treatment within the last 6 months
- Subject must be willing to provide verbal understanding and written informed consent
Exclusion
- Diagnosed with known allergies to facial skincare products
- Nursing, pregnant, or planning to become during the duration of the study
- History of skin cancer within the past 5 years
- Having used oral isotretinoin within the last 12 months
- Having used prescription-strength skin-lightening products within the last 3 months
- Having used any anti-wrinkle, skin-lightening, or other product or topical or systemic medication known to affect skin aging or dyschromia within the last 4 weeks
- Having a health condition and/or pre-existing or dermatologic disorder that, in the Investigator's opinion, may interfere with the outcome of the study
- Having observable sunburn, suntan, scars, excessive facial hair, or other dermal conditions on the face that, in the Investigator's opinion, may influence test results
- Having a history of immunosuppression/immune deficiency disorders, or currently using oral or systemic immunosuppressive medications and biologics, and/or undergoing radiation or chemotherapy
- Using or having regularly used systemic or topical corticosteroids within the past 4 weeks
- Having started a long-term medication within the last 2 months
Key Trial Info
Start Date :
September 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05271136
Start Date
September 30 2020
End Date
October 13 2020
Last Update
March 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS Stephens, Inc.
Richardson, Texas, United States, 75081